Insider Trading Alert - VYFC, CI And NXTM Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 11, 2014, 103 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $337.00 to $15,638,127.00.

Highlighted Stocks Traded by Insiders:

Valley Financial (VYFC) - FREE Research Report

Snyder Kimberly B, who is Evp at Valley Financial, sold 2,720 shares at $19.80 on Dec. 11, 2014. Following this transaction, the Evp owned 7,280 shares meaning that the stake was reduced by 27.2% with the 2,720-share transaction.

The shares most recently traded at $19.76, down $0.04, or 0.2% since the insider transaction. Historical insider transactions for Valley Financial go as follows:

  • 4-Week # shares bought: 6,000
  • 12-Week # shares bought: 6,000
  • 24-Week # shares bought: 6,000
  • 24-Week # shares sold: 365

The average volume for Valley Financial has been 7,900 shares per day over the past 30 days. Valley Financial has a market cap of $95.3 million and is part of the financial sector and banking industry. Shares are up 87.19% year-to-date as of the close of trading on Wednesday.

Valley Financial Corporation operates as the holding company for Valley Bank that provides commercial and retail banking services to small-to-medium sized businesses, professional concerns, and individuals primarily in the Roanoke Valley of Virginia, the United States. The stock currently has a dividend yield of 0.81%. The company has a P/E ratio of 15.3. Currently, there are no analysts who rate Valley Financial a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VYFC - FREE

TheStreet Quant Ratings rates Valley Financial as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and growth in earnings per share. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and weak operating cash flow. Get the full Valley Financial Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Cigna (CI) - FREE Research Report

Henney Jane E Md, who is Director at Cigna, sold 437 shares at $104.16 on Dec. 11, 2014. Following this transaction, the Director owned 14,000 shares meaning that the stake was reduced by 3.03% with the 437-share transaction.

The shares most recently traded at $102.43, down $1.73, or 1.69% since the insider transaction. Historical insider transactions for Cigna go as follows:

  • 4-Week # shares sold: 12,874
  • 12-Week # shares sold: 12,892
  • 24-Week # shares sold: 31,300

The average volume for Cigna has been 1.6 million shares per day over the past 30 days. Cigna has a market cap of $27.3 billion and is part of the health care sector and health services industry. Shares are up 17.06% year-to-date as of the close of trading on Wednesday.

Cigna Corporation, a health services organization, provides insurance and related products and services in the United States and internationally. The stock currently has a dividend yield of 0.04%. The company has a P/E ratio of 14.2. Currently, there are 8 analysts who rate Cigna a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CI - FREE

TheStreet Quant Ratings rates Cigna as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity and growth in earnings per share. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Cigna Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

NxStage Medical (NXTM) - FREE Research Report

Turk Joseph E Jr, who is President at NxStage Medical, sold 1,500 shares at $17.77 on Dec. 11, 2014. Following this transaction, the President owned 112,947 shares meaning that the stake was reduced by 1.31% with the 1,500-share transaction.

The shares most recently traded at $17.31, down $0.46, or 2.66% since the insider transaction. Historical insider transactions for NxStage Medical go as follows:

  • 4-Week # shares bought: 10,150
  • 4-Week # shares sold: 6,500
  • 12-Week # shares bought: 10,150
  • 12-Week # shares sold: 30,232
  • 24-Week # shares bought: 10,150
  • 24-Week # shares sold: 47,811

The average volume for NxStage Medical has been 428,800 shares per day over the past 30 days. NxStage Medical has a market cap of $1.1 billion and is part of the health care sector and health services industry. Shares are up 73% year-to-date as of the close of trading on Wednesday.

NxStage Medical, Inc., a medical device company, develops, manufactures, and markets products for the treatment of kidney failure, fluid overload, and related blood treatments and procedures. Currently, there are 4 analysts who rate NxStage Medical a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on NXTM - FREE

TheStreet Quant Ratings rates NxStage Medical as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. Get the full NxStage Medical Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Stocks Tumble as Trump Comments Lead to Worries Over China Trade Talks

Stocks Tumble as Trump Comments Lead to Worries Over China Trade Talks

Tiffany & Co. Sees a Strong Market in Asia

Tiffany & Co. Sees a Strong Market in Asia

Imagining the Stock Market in 10 Years

Imagining the Stock Market in 10 Years

Video: Jim Cramer on the Markets, Tiffany, Micron Technology and Union Pacific

Video: Jim Cramer on the Markets, Tiffany, Micron Technology and Union Pacific

Red Robin Slumps After Earnings Miss

Red Robin Slumps After Earnings Miss